Treatment Outcomes:
Five months after diagnosis of multiple distant metastases, nivolumab
was started at a dosage of 240 mg/body weight intravenously every 2
weeks. Palliative irradiation was also provided for painful bone
metastases. After four doses of nivolumab, CT showed marked shrinkage of
his metastatic lesions [Figure 3]. After 14 doses, the lesion on the
left ala of the nose, which had recurred repeatedly, had almost
disappeared. After 20 doses, there was improvement in the condition of
the skin on the face [Figure 4]. After 21 doses, the dosage of
nivolumab was changed to 480 mg/body weight every 4 weeks. Mild
leukoplakia appeared around the time of the 26th dose of nivolumab. To
date, a total of 50 doses of nivolumab have been administered, and
complete remission of metastatic lesions has been maintained for 3 years
and 10 months after diagnosis of multiple distant metastases with no
severe immune-related adverse events.